1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Diodes reported first quarter 2026 revenue of $405.5 million, up 22.1% from a year earlier and 3.5% from the prior quarter, and GAAP net income of $15.0 million, or $0.32 per diluted share, compared with a net loss in the prior-year quarter. The company guided second quarter revenue to about $435 million, plus or minus 3%, and non-GAAP adjusted EPS to $0.60, plus or minus $0.10. The results are preliminary and unaudited until the company files its Form 10-Q.
First quarter 2026 revenue was $405.5 million, up 22.1% year over year from $332.1 million.
GAAP net income was $15.0 million, or $0.32 per diluted share, versus a net loss of $4.4 million in the first quarter of 2025.
Non-GAAP adjusted net income was $19.8 million, or $0.43 per diluted share.
Second quarter guidance: revenue about $435 million (plus or minus 3%), GAAP gross margin 32.8% (plus or minus 1%), non-GAAP adjusted EPS $0.60 (plus or minus $0.10).
Dolphin Entertainment reported first-quarter 2026 results for the three months ended March 31, 2026. Revenue rose 5.2% year over year to $12.8 million, but the operating loss, net loss and loss per share all grew from the prior-year quarter, and the company said it reiterated its 2026 expectations for revenue growth, free cash flow and Adjusted EBITDA margin expansion.
Revenue was $12.8 million, up from $12.2 million in Q1 2025.
Operating loss was $2.1 million, compared with $1.8 million a year earlier; net loss was $2.7 million, compared with $2.3 million.
Basic and diluted loss per share was $(0.22), versus $(0.21), on 12,327,974 weighted average shares.
Adjusted EBITDA loss narrowed 25% to approximately $467,000 from $625,000, a non-GAAP measure.
The Eastern Company reported first-quarter 2026 results for the period ended April 4, 2026. Net sales fell 5.7% from a year earlier and net income dropped to $0.6 million, or $0.11 per diluted share, from $1.9 million, or $0.31, with management citing unfavorably priced racks contracts and lower returnable packaging volume. The company reduced debt by $1.0 million and expects the racks impact to be largely behind it by the end of the second quarter.
Net sales were $59.7 million, down 5.7% from $63.3 million in the first quarter of 2025.
Net income was $0.6 million, or $0.11 per diluted share, versus $1.9 million, or $0.31, a year earlier.
Adjusted EBITDA was $3.0 million, compared with $4.6 million, a decrease of about 35%.
Backlog was $82.2 million as of April 4, 2026, up from $81.1 million at January 3, 2026.
TransAct Technologies reported preliminary first-quarter 2026 net sales of $14.4 million, up 10% year over year, and net income of $766 thousand, or $0.07 per diluted share, compared with $19 thousand a year earlier. The company reiterated its 2026 net sales guidance of $55 million to $57 million, raised its adjusted EBITDA guidance to $1 million to $1.75 million, and authorized a $3 million share buyback, while CFO Steven A. DeMartino retires on June 30, 2026, with Robert Campbell succeeding him.
Net sales were $14.4 million, up from $13.1 million, with casino and gaming sales up 24% and recurring FST revenue of $3.3 million, up 26%.
Net income was $766 thousand, or $0.07 per diluted share, versus $19 thousand, or $0.00, in Q1 2025; adjusted EBITDA was $1.4 million versus $544 thousand.
2026 net sales guidance was reiterated at $55 million to $57 million; adjusted EBITDA guidance was raised to $1 million to $1.75 million.
The Board authorized repurchases of up to $3 million of common stock over 12 months starting May 12, 2026; CFO Steven A. DeMartino retires June 30, 2026, and Robert Campbell, the Controller since June 2022, succeeds him.
Astronics reported first-quarter 2026 sales up 12.0% to $230.6 million and net income of $25.5 million, or $0.67 per diluted share, compared with $0.26 a year earlier. The company raised its 2026 revenue guidance to $970 million to $1 billion and reported record backlog of $734.3 million, which shareholders should weigh alongside cash from operations of $10.6 million in the quarter.
Sales rose 12.0% to $230.6 million; Aerospace sales rose 11.7% to $213.8 million
Diluted EPS was $0.67 versus $0.26; net income was $25.5 million versus $9.5 million
2026 revenue guidance raised to $970 million to $1 billion; second-quarter sales expected at $245 million to $250 million
Cash from operations was $10.6 million and capital expenditures were $11.2 million in the quarter
Atea Pharmaceuticals reported a first-quarter 2026 net loss of $45.4 million, or $0.57 per share, up from $34.3 million, or $0.40 per share, a year earlier. Research and development spending rose to $41.1 million, driven by Phase 3 hepatitis C trial costs, and cash, cash equivalents and marketable securities fell to $256.0 million from $301.8 million at December 31, 2025. The filing reports no revenue, and the company said its two hepatitis C Phase 3 topline readouts are expected in mid-2026 and around year-end 2026.
Net loss was $45.4 million ($0.57 per share) for the three months ended March 31, 2026, versus $34.3 million ($0.40 per share) a year earlier.
Research and development expenses increased $11.6 million to $41.1 million; general and administrative expenses decreased $2.6 million to $6.9 million.
Cash, cash equivalents and marketable securities were $256.0 million at March 31, 2026, down from $301.8 million at December 31, 2025.
C-BEYOND Phase 3 topline results are expected mid-2026; C-FORWARD topline results are expected around year-end 2026.
Black Rock Coffee Bar reported first quarter 2026 total revenue of $55.5 million, up 23.7% from the prior year, and net income of $1.8 million versus a net loss of $0.9 million a year earlier. The company reaffirmed its full year 2026 guidance for total revenue of $255 to $257 million and adjusted EBITDA of $33.5 to $34.5 million, while same store sales growth slowed to 5.2% from 9.2%.
Total revenue of $55.5 million, up 23.7% from $44.8 million in the prior year period
Same store sales growth of 5.2%, down from 9.2% in the first quarter of 2025
Net income of $1.8 million versus a net loss of $0.9 million; adjusted EBITDA of $7.4 million, up 23.5%
Full year 2026 guidance reaffirmed: total revenue $255 to $257 million; adjusted EBITDA $33.5 to $34.5 million
Karman Holdings reported first-quarter fiscal 2026 revenue of $151.2 million, up 51.0% from a year earlier, and swung to net income of $7.8 million from a net loss of $4.8 million. The company raised its full-year 2026 outlook to $720 million to $735 million in revenue and $208.5 million to $219.5 million in non-GAAP adjusted EBITDA, which shareholders will see as a sign of stronger expected operating results for the year.
Q1 2026 revenue was $151.2 million, up 51.0% from $100.1 million in Q1 2025.
Net income was $7.8 million, or $0.06 per diluted share, versus a net loss of $4.8 million, or $0.04 per share, a year earlier.
Non-GAAP adjusted EBITDA was $44.8 million, up from $30.3 million, and backlog reached $1.0 billion as of March 31, 2026.
Full-year 2026 revenue and adjusted EBITDA guidance were both increased, excluding future acquisitions.
Palisade Bio reported a first-quarter 2026 net loss of $9.6 million, up from $2.2 million a year earlier, as research and development and general and administrative expenses rose sharply. The company had $132.6 million in cash and cash equivalents at March 31, 2026, and said it expects that cash to fund operations through its Phase 2 ulcerative colitis and Crohn's disease readouts, but the filing reports no revenue and a much larger loss for shareholders.
Net loss was $9.6 million, or $0.05 per share, for the three months ended March 31, 2026, versus $2.2 million, or $0.47 per share, a year earlier.
Research and development expenses rose to $6.4 million from $1.0 million; general and administrative expenses rose to $4.4 million from $1.4 million.
Cash and cash equivalents were $132.6 million at March 31, 2026, down from $133.4 million at December 31, 2025.
Phase 2 ulcerative colitis trial initiation is targeted for Q3 2026, and the Phase 2 UC readout is expected in 2H 2027.
QuickLogic reported fiscal first quarter 2026 revenue of $5.1 million, up 16.8% from a year earlier and 35.3% from the fourth quarter of 2025. The GAAP net loss was $2.2 million, or $0.13 per share, compared with $0.14 per share a year earlier, but GAAP gross margin fell to 36.5% from 43.4%. Cash, cash equivalents and restricted cash dropped to $6.0 million from $18.8 million at year-end after the company repaid a $15.0 million revolving line of credit.
Revenue of $5.1 million, up 16.8% year over year; new product revenue of $4.3 million, up 14.5%
GAAP net loss of $2.2 million, or $0.13 per share, versus a $5.9 million loss ($0.35 per share) in the fourth quarter of 2025
GAAP gross margin of 36.5%, down from 43.4% in the first quarter of 2025
Cash and restricted cash of $6.0 million at March 29, 2026, down from $18.8 million at December 28, 2025; revolving line of credit balance was $0
Intellicheck reported first-quarter 2026 revenue of $5,524,000, up 13% from a year earlier, and net income of $636,000, or $0.03 per diluted share, compared with a net loss of $318,000 in the first quarter of 2025. For shareholders, the filing shows a swing to profit in the quarter, with the company reporting $10,062,000 in cash and no debt as of March 31, 2026.
Revenue rose 13% to $5,524,000 from $4,894,000 in Q1 2025, with SaaS revenue of $5,514,000.
Net income was $636,000, or $0.03 per diluted share, versus a net loss of $318,000, or $0.02 per share, a year earlier.
Adjusted EBITDA was $935,000 compared with a loss of $17,000; cash and cash equivalents were $10,062,000 at March 31, 2026.
TherapeuticsMD reported net income from continuing operations of $103 thousand for the quarter ended March 31, 2026, compared with a net loss of $636 thousand a year earlier. License revenue rose to $724 thousand, mainly from the Mayne License Agreement, while operating expenses fell 13.6%. The company also said it is still exploring strategic alternatives, including a possible acquisition, merger, or sale of assets, with no timetable set.
Net income from continuing operations was $103 thousand, versus a net loss of $636 thousand in Q1 2025.
License revenue was $724 thousand, up $331 thousand from $393 thousand in Q1 2025.
Total operating expenses were $1,447 thousand, down $227 thousand or 13.6% from $1,674 thousand.
Cash and cash equivalents totaled $8.4 million as of March 31, 2026; the strategic review has no set timetable.
IPM reported first-quarter 2026 revenue of $6.35 million, up 15.2% from a year earlier, and its operating loss narrowed by 42.4%. Net results turned to a $660,214 loss from $808,530 of net income, because the prior-year period included an income tax benefit of about $2.1 million that did not recur.
Total revenue was $6,354,751 versus $5,518,038 for Q1 2025, up 15.2%; procurement revenue rose 78.4% and core managed IT revenue rose 19%.
Loss from operations was $768,182 versus $1,333,927 a year earlier.
Net loss was $660,214, or $(0.05) per share, versus net income of $808,530, or $0.06 per share, in Q1 2025.
Net cash used in operating activities was $195,712, and cash and cash equivalents totaled $8.1 million at March 31, 2026, including $1.0 million of restricted cash.
PepGen reported a first quarter 2026 net loss of $17.8 million, or $(0.26) per share, down from $30.2 million, or $(0.92) per share, a year earlier, as research and development expenses fell to $13.0 million from $25.4 million. The company also disclosed that the FDA placed a partial clinical hold on its FREEDOM2 study of PGN-EDODM1, which PepGen says relates to previously submitted preclinical studies and has not affected the ongoing trial's timing, and that cash and marketable securities were $132.3 million as of March 31, 2026.
Q1 2026 net loss was $17.8 million, or $(0.26) per share, versus $30.2 million, or $(0.92) per share, in Q1 2025.
Research and development expenses were $13.0 million, compared with $25.4 million a year earlier; general and administrative expenses were $5.9 million in both periods.
The FDA placed a partial clinical hold on the FREEDOM2 study, tied to questions about previously submitted preclinical pharmacology and toxicology studies.
Cash, cash equivalents and marketable securities were $132.3 million at March 31, 2026, down from $148.5 million at December 31, 2025, and PepGen expects this to fund operations into the second half of 2027.
Lineage Cell Therapeutics reported first quarter 2026 results, with total revenues of $1.7 million, up from $1.5 million a year earlier. The net loss attributable to Lineage widened to $4.8 million, or $0.02 per share basic and $0.03 diluted, from $4.1 million, or $0.02 per share, in the prior-year quarter. The company said its $53.4 million in cash, cash equivalents and marketable securities is expected to support planned operations into Q2 2028.
Total revenues were $1.7 million for the quarter ended March 31, 2026, up $0.2 million, driven mainly by collaboration revenue under the new research collaboration agreement with William Demant Invest A/S (WDI).
Loss from operations was $7.6 million, compared with $6.5 million a year earlier, as total operating expenses rose to $9.3 million from $8.0 million.
Other income of $2.8 million, including a $2.3 million change in fair value of warrant liability, partly offset the operating loss.
Cash, cash equivalents and marketable securities totaled $53.4 million as of March 31, 2026.
Lumexa Imaging reported first quarter 2026 revenue of $252.5 million, up 3.1% from $245.0 million a year earlier, and swung to net income of $1.7 million from a net loss of $7.7 million. The company reiterated its full year 2026 guidance and said it is adding four centers, including two tuck-in acquisitions and two de novo centers.
Consolidated revenue of $252.5 million, up 3.1% from $245.0 million; same-center advanced volume growth of 5.6%
Net income of $1.7 million (GAAP EPS $0.02) versus a net loss of $7.7 million (EPS of $(0.11)) a year earlier
Adjusted EBITDA of $51.2 million versus $51.0 million, a 20.3% margin; Adjusted EPS of $0.18 versus $0.04
Full year 2026 guidance reiterated: revenue of $1.045 to $1.097 billion and Adjusted EBITDA of $234 to $242 million
Resideo reported first quarter 2026 net revenue of $1.91 billion, up 8% year-over-year, with adjusted EBITDA of $215 million, up 28%, and net income of $38 million compared with $6 million a year earlier. The company said revenue, adjusted EBITDA and adjusted EPS were all above the high end of its outlook range, and it reaffirmed its full-year 2026 outlook. Operating cash use widened to $145 million from $65 million, which the company attributed mainly to business separation activities.
Net revenue of $1,912 million, up 8% from $1,770 million, and above the high end of the outlook range
Net income of $38 million versus $6 million; GAAP diluted EPS of $0.17 versus a loss of $0.02
Adjusted EBITDA of $215 million, up 28% from $168 million; Adjusted EPS of $0.65 versus $0.63
Cash used by operating activities of $145 million versus $65 million; full-year 2026 outlook reaffirmed and second-quarter revenue outlook of $1,916 million to $1,940 million given
Nextpower reported fiscal fourth-quarter 2026 revenue of $881 million and GAAP diluted EPS of $0.97, both below the year-earlier quarter, while full-year fiscal 2026 revenue rose to $3.56 billion and GAAP diluted EPS reached $3.84. The company raised its fiscal 2027 revenue outlook to $3.8 billion to $4.1 billion from $3.6 billion to $3.8 billion, and it also announced a planned acquisition of power conversion product lines subject to Spanish government approval.
Q4 FY26 revenue $881 million vs. $924 million in Q4 FY25; GAAP diluted EPS $0.97 vs. $1.05
Full-year FY26 revenue $3.56 billion; GAAP diluted EPS $3.84 vs. $3.47 in FY25
FY27 outlook: revenue $3.8 billion to $4.1 billion; Adjusted EBITDA $825 million to $900 million
Robert Vinje appointed Chief Operating Officer effective June 15, 2026; Marco Miller moves to Chief Project Development Officer
GrowGeneration reported first quarter 2026 results on May 12, 2026, in a press release furnished as Exhibit 99.1 to a Form 8-K. Net sales rose 7.5% to $38.4 million and the GAAP net loss narrowed to $4.9 million from $9.4 million, while gross profit margin fell to 25.4% from 27.2%. The company reaffirmed its full-year 2026 revenue outlook of $162 million to $168 million and its expectation of approximately breakeven Adjusted EBITDA, and reported $41.1 million in cash and marketable securities with no debt as of March 31, 2026.
Net sales were $38.4 million, up from $35.7 million in the first quarter of 2025.
GAAP net loss was $4.9 million, or $0.08 per share, compared with a net loss of $9.4 million, or $0.16 per share, a year earlier.
Gross profit margin was 25.4%, down from 27.2%; Adjusted EBITDA loss narrowed to $1.6 million from $4.0 million.
The 2026 outlook was reaffirmed at $162 million to $168 million in net revenue, with second-quarter 2026 net sales expected at $42 million to $44 million.
Verrica Pharmaceuticals reported first quarter 2026 total revenue of $5.0 million, up from $3.4 million a year earlier, with U.S. YCANTH net product revenue of $4.3 million. The net loss was $9.7 million, or $0.45 per share, compared with $9.7 million, or $1.03 per share, in the first quarter of 2025, and cash fell to $20.6 million at March 31, 2026 from $30.1 million at December 31, 2025.
Total revenue was $5.0 million versus $3.4 million in Q1 2025; U.S. YCANTH net product revenue was $4.3 million versus $3.4 million.
Net loss was $9.7 million, or $0.45 per share, versus $9.7 million, or $1.03 per share, in Q1 2025.
Non-GAAP net loss was $8.8 million, or $0.41 per share, versus $8.3 million, or $0.88 per share, a year earlier.
Cash was $20.6 million at March 31, 2026, down from $30.1 million at December 31, 2025.
NeuroPace reported first quarter 2026 results and raised its full-year 2026 revenue guidance to $99 million to $101 million, up from $98 million to $100 million. Revenue excluding DIXI Medical grew 20.1% year over year to $22.0 million, while GAAP revenue was $22.1 million compared with $22.5 million a year earlier. The GAAP net loss was $6.7 million, slightly wider than the $6.6 million loss in the first quarter of 2025, and cash and equivalents fell to $54.8 million from $61.2 million at the prior quarter end.
Q1 2026 revenue excluding DIXI Medical was $22.0 million, up 20.1% year over year; RNS System revenue was $21.7 million, up 19.5%.
Full-year 2026 revenue guidance raised to $99 million to $101 million; Adjusted EBITDA loss guidance narrowed to ($8.5) million to ($9.5) million from ($9.0) million to ($10.0) million.
GAAP net loss was $6.7 million in Q1 2026 versus $6.6 million in Q1 2025.
DIXI Medical will be reported as discontinued operations beginning with the second quarter 2026 results.
IZEA Worldwide reported first-quarter 2026 revenue of $6.6 million, down $1.4 million (18%) from $8.0 million a year earlier, and a net loss of $0.8 million, or $(0.04) per share, versus a net loss of $0.1 million, or $(0.01) per share. The company said the revenue decline mainly reflects exiting small and mid-size business accounts, and it attributed lower bookings to contract timing at large enterprise clients.
Revenue was $6.6 million, down 18% from $8.0 million, driven mainly by shedding small, unprofitable SMB accounts.
Managed Services bookings declined 17% to $6.3 million, which the company said primarily reflects contract timing within several large enterprise accounts.
Net loss was $0.8 million, or $(0.04) per share, compared with a net loss of $0.1 million, or $(0.01) per share, a year earlier.
Cash and cash equivalents were $46.5 million at March 31, 2026, down $4.4 million during the quarter, and the company has no outstanding long-term debt.
Evolv Technology reported first-quarter 2026 revenue of $46.3 million, up 45% from a year earlier, and ending annual recurring revenue of $127.3 million, up 20%. The company raised its 2026 total revenue outlook to $175 million to $180 million, but its net loss widened to $5.0 million from $1.7 million, which shareholders should weigh against the higher sales and guidance.
Q1 2026 revenue was $46.3 million, up 45% from $32.0 million in Q1 2025.
Net loss was $5.0 million, or $(0.03) per share, versus $1.7 million, or $(0.01) per share, in Q1 2025.
2026 total revenue outlook raised to $175 million to $180 million from $172 million to $178 million issued March 10, 2026.
Cash, cash equivalents and marketable securities were $61.1 million as of March 31, 2026.
Electromed reported results for the quarter ended March 31, 2026, with net revenues of $18.6 million, up 18.4% from $15.7 million a year earlier, and net income of $3.0 million, or $0.35 per diluted share, up 58.8%. The company also said it updated its investor presentation for meetings with investors and analysts.
Net revenues of $18.6 million, up 18.4% from $15.7 million in the third quarter of fiscal 2025.
Net income of $3.0 million, or $0.35 per diluted share, versus $1.9 million, or $0.21 per diluted share, a year earlier.
Operating income of $3.8 million, or 20.3% of net revenues, up 76.0% from $2.1 million.
As of March 31, 2026, cash was $17.0 million with no debt; nine-month share repurchases totaled $3.9 million.
Beachbody reported first-quarter 2026 revenue of $54.3 million, down from $72.4 million a year earlier, while net income was $2.3 million compared with a net loss of $5.7 million. The company also gave second-quarter 2026 revenue guidance of $46 million to $51 million and adjusted EBITDA guidance of $3 million to $6 million, so shareholders face shrinking sales alongside improved profitability.
Total revenue was $54.3 million, down 25.0% from $72.4 million; digital subscriptions totaled 0.81 million, down 20.6% from 1.02 million.
Operating income was $3.1 million, compared with an operating loss of $3.7 million a year earlier; net income was $2.3 million versus a net loss of $5.7 million.
Adjusted EBITDA was $8.0 million, up from $3.7 million, while free cash flow was negative $1.7 million compared with positive $1.6 million.
Second-quarter 2026 outlook calls for revenue of $46 million to $51 million and adjusted EBITDA of $3 million to $6 million.
Hour Loop reported first-quarter 2026 net revenue of $29.9 million, up 16% from $25.8 million a year earlier, and net income of $0.82 million, up from $0.65 million. The company reaffirmed its full-year 2026 net revenue guidance of $143.0 million to $163.0 million and net income guidance of $0.75 million to $1.5 million, but cash used in operating activities rose to $2.2 million and gross margin fell to 53.5%.
Net revenues rose 16% to $29.9 million, versus $25.8 million a year earlier.
Net income was $0.82 million, or $0.02 per diluted share, versus $0.65 million, or $0.02 per diluted share, a year earlier.
Gross margin fell to 53.5% from 54.7%, mainly due to higher storage fees and inbound costs.
Cash used in operating activities was $2.2 million, versus $0.0 million a year earlier; cash was $0.9 million as of March 31, 2026, down from $3.8 million at December 31, 2025.
Paysign reported first-quarter 2026 revenue of $28.04 million, up 50.8% from a year earlier, and net income of $5.44 million, or $0.09 per diluted share, up 110.3% from $2.59 million. The company reiterated its full-year 2026 revenue guidance of $106.5 million to $110.5 million, and said it expects to finish in the upper half of its guidance ranges.
Q1 2026 revenue of $28.04 million, up from $18.6 million in Q1 2025; pharma revenue rose 81.9% to $15.68 million.
Net income of $5.44 million, or $0.09 per diluted share, versus $2.59 million, or $0.05 per diluted share, in Q1 2025.
Full-year 2026 guidance reiterated: revenue of $106.5 million to $110.5 million and diluted EPS of $0.21 to $0.26; Q2 2026 revenue guidance is $26.2 million to $26.7 million.
Unrestricted cash was $20.55 million at March 31, 2026, with zero bank debt.
Immunome reported first-quarter 2026 results with no collaboration revenue, compared with $2.9 million a year earlier. Its net loss widened to $53.8 million from $41.6 million as research and development and general and administrative costs rose. The company said it submitted a New Drug Application for varegacestat to the FDA in April 2026 and expects its $582.7 million in cash to fund operations into 2028.
Net loss was $53.8 million for the quarter ended March 31, 2026, versus $41.6 million a year earlier.
Collaboration revenue was $0 versus $2.9 million in the first quarter of 2025.
Research and development expenses were $46.4 million, up from $36.9 million; general and administrative expenses were $13.0 million, up from $10.7 million.
Net loss per share was $0.48, compared with $0.52, on 113,136,836 weighted-average shares versus 79,410,354 a year earlier.
Nkarta reported first quarter 2026 results with a net loss of $27.8 million, or $0.37 per share, down from $32.0 million, or $0.43 per share, a year earlier. G&A expenses fell to $5.9 million from $12.4 million, while cash, cash equivalents and investments declined to $266.7 million from $295.1 million at year-end 2025, and the company expects its current operating plan to be funded into 2029.
Net loss of $27.8 million ($0.37 per share) for Q1 2026, versus $32.0 million ($0.43 per share) in Q1 2025
R&D expenses were $25.0 million, up from $24.2 million; G&A expenses fell to $5.9 million from $12.4 million
Cash and investments were $266.7 million on March 31, 2026, down from $295.1 million on December 31, 2025
Company expects current cash to fund its operating plan into 2029
TriSalus Life Sciences reported first quarter 2026 revenue of $8.9 million, down 2.9% from a year earlier, and revised its 2026 revenue guidance to $54 million to $57 million. Net income was $1.5 million, or $0.03 per share, but that result reflected $11.3 million of non-cash derivative gains, while the operating loss widened, so shareholders face a mixed picture.
Q1 2026 revenue was $8.9 million, down 2.9% from $9.2 million in Q1 2025, which the company attributed mainly to its commercial expansion.
Operating loss widened to $8.4 million from $7.3 million, and adjusted EBITDA loss widened to $5.8 million from $5.5 million.
Net income attributable to common stockholders was $1.5 million, or $0.03 per share, versus a net loss of $11.1 million, or $(0.39) per share, a year earlier; the company cited $11.3 million of non-cash fair value gains on derivatives.
2026 revenue guidance was revised to $54 million to $57 million, citing lower Q1 revenue and delayed FDA clearance timing for TriNav Advance; cash totaled $56.6 million on March 31, 2026, after a $46.0 million gross equity raise.
Curis reported a first-quarter 2026 net loss of $24.2 million, or $1.25 per share, compared with $10.6 million, or $1.25 per share, a year earlier. Revenue fell to zero after the company sold its Erivedge royalties to Oberland in the fourth quarter of 2025, and a change in the fair value of a warrant liability drove most of the larger loss. The company says its planned operations into the second half of 2027 depend on warrant exercises tied to a clinical milestone.
Q1 2026 revenue was zero, compared with $2.4 million in Q1 2025, after the Erivedge royalty sale to Oberland.
Other expense was $12.7 million, mainly from the change in fair value of the warrant liability tied to the January 2026 PIPE Financing, versus $0.5 million a year earlier.
Cash and cash equivalents were $15.0 million at March 31, 2026; the filing states the company does not have sufficient cash to support operations for the next 12 months.
Up to $20.2 million from Series B warrant exercises depends on announcing dosing of the fifth CLL patient, which is expected later this year.
Energy Focus reported first quarter 2026 results for the period ended March 31, 2026, with net sales of $0.9 million, up 54.1% from $0.6 million a year earlier. The net loss narrowed to $0.1 million, or $(0.02) per share, from $0.3 million, or $(0.05) per share, while gross profit margin fell to 23.3% from 31.5%. The company said its planned Japan expansion depends on securing additional capital, and it cited current liquidity constraints.
Net sales of $0.9 million rose 54.1% year over year; military maritime product sales rose 52.1% and commercial sales rose 56.7%.
Gross profit margin decreased to 23.3% from 31.5% in the first quarter of 2025, mainly due to higher inventory reserves and tariff impacts.
Net loss was $0.1 million, or $(0.02) per share, compared with $0.3 million, or $(0.05) per share, a year earlier.
Cash was $1.1 million at March 31, 2026, and the company said its initiatives depend on securing additional capital.
ACCESS Newswire reported first-quarter 2026 results for the three months ended March 31, 2026. Revenue fell 3% year over year to $5.3 million, while the net loss from continuing operations narrowed to $0.6 million, or $0.16 per diluted share, from $0.8 million, or $0.20 per share, a year earlier. Revenue and profit moved in opposite directions, and the filing gives no financial guidance.
Revenue was $5.3 million, down 3% from $5.5 million in Q1 2025 and down 8% from $5.8 million in Q4 2025.
Net loss from continuing operations was $611,000, or $0.16 per diluted share, compared with $765,000, or $0.20 per share, in Q1 2025.
Adjusted EBITDA was $564,000 in both Q1 2026 and Q1 2025; gross margin fell to 74% from 78%.
Subscription customers reached 1,119, and average ARR per customer rose to $12,803 from $11,139 a year earlier.
Xilio Therapeutics reported first quarter 2026 results, with collaboration and license revenue of $12.6 million, up from $2.9 million a year earlier, and a net loss of $9.5 million, down from $13.3 million. Net loss per share improved to $0.58 from $2.49, and the company said its cash runway now extends into early 2028.
Collaboration and license revenue was $12.6 million for the quarter ended March 31, 2026, versus $2.9 million a year earlier, mainly from AbbVie and Gilead agreements.
R&D expenses rose to $19.8 million from $8.3 million, while G&A expenses fell to $6.9 million from $8.5 million.
Cash and cash equivalents were $150.3 million at March 31, 2026, versus $137.5 million at December 31, 2025, after $37.3 million in net proceeds from a February 2026 follow-on offering.
Xilio achieved a $6.0 million development milestone under the AbbVie collaboration in the second quarter of 2026 and plans to submit an XTX501 IND application in mid-2026.
Under Armour reported fourth-quarter and full-year fiscal 2026 results on May 12, 2026. Revenue fell 1% to $1.2 billion in the quarter and 4% to $5.0 billion for the year, and the company posted a full-year net loss of $496 million. It also raised the total cost of its fiscal 2025 restructuring plan to approximately $305 million and gave initial fiscal 2027 guidance that includes operating income of $96 million to $116 million.
Q4 fiscal 2026 revenue fell 1% to $1.2 billion; net loss was $43 million, or $0.10 per share, versus a $67 million loss ($0.16 per share) a year earlier.
Full-year net loss was $496 million ($1.16 per share), including a $247 million valuation allowance on U.S. federal deferred tax assets.
Total fiscal 2025 restructuring plan costs were raised to approximately $305 million from the previous $255 million, with completion expected by December 31, 2026.
Fiscal 2027 outlook: operating income of $96 million to $116 million and GAAP diluted loss per share of breakeven to $0.04.
Ambiq Micro reported first quarter 2026 net sales of $25.1 million, up 59.3% from $15.7 million a year earlier and up 20.8% from the fourth quarter. The net loss was $10.2 million, or $0.50 per share, compared with $8.3 million, or $18.96 per share, a year earlier, and the company guided second quarter net sales to $31.0 million to $32.0 million.
Q1 2026 net sales were $25.1 million, up 59.3% year over year and up 20.8% from the prior quarter.
GAAP gross margin was 43.5%, down from 53.3% a year earlier; non-GAAP gross margin was 46.2%.
GAAP net loss was $10.2 million ($0.50 per share) versus $8.3 million ($18.96 per share) in Q1 2025.
Q2 2026 outlook: net sales of $31.0 million to $32.0 million and non-GAAP net loss per share of ($0.29) to ($0.23).
Zebra Technologies reported first-quarter 2026 net sales of $1,495 million, up 14.3% from a year earlier, with organic growth of 4.3%. The company said it raised its full-year 2026 outlook, now expecting non-GAAP diluted EPS of $18.30 to $18.70, though GAAP net income was roughly flat, down 0.7%, at $135 million.
Net sales $1,495 million vs. $1,308 million a year earlier; organic growth 4.3%.
GAAP diluted EPS $2.72 vs. $2.62; non-GAAP diluted EPS $4.75 vs. $4.02.
Full-year 2026 outlook: sales growth of 10% to 14% and non-GAAP diluted EPS of $18.30 to $18.70.
Share repurchases of $300 million in the quarter; free cash flow of $163 million.
Ralliant reported first-quarter 2026 revenue of $535 million, up 11% from a year earlier, and raised its full-year 2026 outlook. GAAP net earnings fell to $44 million, or $0.39 per diluted share, from $63.9 million, or $0.57, a year earlier, so shareholders see higher sales alongside lower reported profit. The company also raised its share repurchase authorization to $500 million.
Revenue of $535 million, up 11% year over year and up 9% organically; net earnings of $44 million, or $0.39 per diluted share, versus $0.57 a year earlier
Full-year 2026 guidance: revenue of $2.185 to $2.245 billion and adjusted EPS of $2.53 to $2.69
Second-quarter 2026 guidance: revenue of $540 to $556 million and adjusted EPS of $0.58 to $0.64
Share repurchase authorization raised to $500 million on May 8, 2026, including a planned $100 million accelerated share repurchase in the second quarter
Prelude Therapeutics reported first quarter 2026 results, with a net loss of $10.4 million, or $0.13 per share, compared with $32.1 million, or $0.42 per share, a year earlier. The company recorded $4.6 million of revenue, versus none in the prior-year period, and lower research and development and general and administrative expenses. It said its cash runway now extends into the second quarter of 2028, based on preliminary estimates that reflect an underwritten offering with about $90 million in gross proceeds completed after March 31.
Net loss was $10.4 million, or $0.13 per share, for the three months ended March 31, 2026, versus $32.1 million, or $0.42 per share, a year earlier.
Revenue was $4.6 million in the quarter, compared with no revenue in the prior-year period.
Research and development expense fell to $13.6 million from $28.8 million, mainly due to lower spending on SMARCA2 trials paused in 2025.
Cash, cash equivalents, restricted cash and marketable securities were $84.8 million on March 31, 2026, before the offering of about $90 million in gross proceeds.
SOLV Energy reported first-quarter 2026 revenue of $677 million, up 66% from a year earlier, and a net loss of $27 million, which included a one-time, non-cash expense of $52 million tied to modifying legacy equity awards from its IPO reorganization. The company raised its full-year 2026 Adjusted EBITDA guidance to $435 million to $455 million. For shareholders, operating growth was strong, but the reported loss widened and the company's chief strategy officer stepped down from that role.
Revenue was $677 million versus $408 million a year earlier; Adjusted EBITDA was $93 million, up 174% from $34 million.
Net loss was $27 million, including a one-time, non-cash expense of $52 million from modifying legacy equity awards; basic and diluted loss per share was $0.20 for February 12 to March 31, 2026.
Full-year 2026 guidance: revenue of $3.720 billion to $3.820 billion and Adjusted EBITDA of $435 million to $455 million.
Erik Johnson resigned as Chief Strategy Officer effective May 11, 2026, and will remain an employee through the end of 2026.
Broadwind reported first quarter 2026 revenue of $34.1 million, down 7.5% from $36.8 million a year earlier, and a net loss of $0.5 million, or $0.02 per share, versus a $0.4 million loss in the prior year. Revenue fell mainly because Heavy Fabrications sales dropped 35%, while orders rose 23% and the company said it is exiting the wind tower business and selling its Abilene facility.
Q1 2026 revenue was $34.1 million, down from $36.8 million; Adjusted EBITDA was $2.2 million, down from $2.4 million
Net loss was $0.5 million ($0.02 per diluted share), compared with a $0.4 million loss ($0.02 per share) in Q1 2025
Total orders rose 23% to $37.4 million; Industrial Solutions and Gearing revenue grew 64% and 42%, respectively
Net proceeds of approximately $17.2 million from the April 2026 sale of the Abilene facility; the company expects to exit the wind market in September 2026
Janus International reported first-quarter 2026 results for the quarter ended April 4, 2026. Revenue rose 5.8% to $222.7 million, but net income fell to $0.2 million from $10.8 million a year earlier, and adjusted EBITDA fell 14.1% to $33.0 million. The company reaffirmed its full-year 2026 guidance, which calls for total revenue of $940 million to $980 million and adjusted EBITDA of $165 million to $185 million.
Revenue was $222.7 million, up 5.8% from $210.5 million; New Construction revenue rose 10.9%, and the Kiwi II Construction acquisition contributed $18.1 million.
Net income was $0.2 million, or $0.00 per diluted share, versus $10.8 million, or $0.08 per diluted share, a year earlier; adjusted diluted EPS was $0.01 versus $0.13.
Full-year 2026 guidance was reaffirmed: total revenue of $940 million to $980 million and adjusted EBITDA of $165 million to $185 million.
During the quarter the company repurchased about 2.9 million shares for $15.7 million, and free cash flow was $33.4 million.
Via reported first-quarter 2026 revenue of $127.4 million, up 29% from a year earlier, and Adjusted EBITDA of negative $5.8 million, improved from negative $8.3 million. GAAP net loss widened to $20.1 million from $16.3 million, but loss per share narrowed to $0.25 from $1.28 because of a much larger share count. The company guided to full-year 2026 platform revenue of $547.0 million to $550.0 million and expects positive Adjusted EBITDA in the fourth quarter of 2026.
Q1 2026 revenue $127.4 million, up 29% year over year; Platform Annual Run-Rate Revenue $509.7 million
Net loss $20.1 million vs. $16.3 million a year earlier; net loss per share $(0.25) vs. $(1.28)
Adjusted EBITDA of negative $5.8 million vs. negative $8.3 million; Adjusted Net Loss $3.8 million vs. $8.6 million
Guidance: Q2 2026 platform revenue $132.5 million to $134.0 million; full-year 2026 $547.0 million to $550.0 million; Q4 2026 Adjusted EBITDA above $0
Aramark reported fiscal second-quarter 2026 revenue of $4.9 billion, up 15% year over year, with GAAP diluted EPS of $0.38 versus $0.23 and Adjusted EPS of $0.49, up 40% on a constant currency basis. The company raised its fiscal 2026 organic revenue growth outlook to the high end of its previously stated 7% to 9% range and reaffirmed its profit and leverage targets, which points to continued growth for shareholders, though the filing says a new hyperscaler agreement is not yet in the outlook.
Revenue of $4.9 billion, up 15%; organic revenue up 12%, with about 3% from the calendar shift
GAAP diluted EPS of $0.38 versus $0.23; Adjusted EPS of $0.49, up 40% on a constant currency basis
Fiscal 2026 organic revenue growth now expected at the high end of 7% to 9%
Adjusted Operating Income growth of 12% to 17% and Adjusted EPS growth of 20% to 25% reaffirmed
Ducommun reported first-quarter 2026 results for the period ended April 4, 2026, with net revenue of $209.0 million, up from $192.5 million a year earlier. Net income rose to $9.9 million, or $0.64 per diluted share, from $1.4 million, or $0.09 per share, a year earlier. The filing contains no change to financial guidance, and the company said it expects some destocking headwinds in the remaining quarters of 2026.
Net revenue was $209.0 million, up from $192.5 million in Q1 2025, with commercial aerospace revenue up $12.5 million.
Diluted EPS was $0.64 versus $0.09; non-GAAP adjusted diluted EPS was $0.75 versus $0.23.
Adjusted EBITDA was $35.4 million, or 16.9% of revenue, compared with $29.7 million, or 15.4%, a year earlier.
Q1 2025 figures are shown as restated in the company's Form 10-K/A filed May 8, 2026.
Qnity reported first-quarter 2026 net sales of $1.3 billion, up 18% from a year earlier, and raised its full-year 2026 guidance across all metrics. GAAP net income fell 19% to $162 million and GAAP diluted EPS fell 22% to $0.72, while adjusted EPS rose 33% to $1.08, a non-GAAP measure. Shareholders get higher sales and a raised outlook, but the GAAP profit decline is the key counterpoint.
Q1 2026 net sales $1,315 million, up 18% year over year; organic sales up 17%
GAAP net income $162 million, down 19%; GAAP diluted EPS $0.72, down 22%
Adjusted EPS $1.08, up 33%; adjusted operating EBITDA $411 million, up 22%
Full-year 2026 guidance: net sales $5.225 billion to $5.375 billion; adjusted EPS $3.80 to $4.14
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.